

## Aims

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, lifestyle and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 20<sup>th</sup> AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

## Addressed to

Gynaecologists, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

## Educational material

The event educational material can be downloaded starting November 10<sup>th</sup> on askit.accmed.org

# **Programme**

15.00 Discussion

Thursday, October 24	
10.30	Introduction to the Conference Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat
	SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGIMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly
11.00	Gene expression tools in early-stage HR+/HER2- breast cancer: questioning the grey areas Alberto Zambelli
11.20	The immune system and breast cancer: TNBC and beyond Marleen Kok
11.40	DNA NGS-based biomarkers to inform treatment sequence in advanced breast cancer Mafalda Oliveira
12.00	Tackling the biological diversity in HER2-positive breast cancer: clinical implications Aleix Prat
12.20	Discussion
12.50	Lunch
	SESSION II – LOCOREGIONAL Tx AND GENOMICS Chairpersons: Jacek Jassem, Eleftherios Mamounas
14.00	Surgery of the axilla: is less always more? Oreste Gentilini
14.20	Navigating RT option according to genetic risk profiles Philip Poortmans
14.40	<b>Evolving concepts in genetic testing: finding the balance</b> Angela Toss

	AND POST-NEOADJUVANT THERAPY Chairpersons: Pierfranco Conte, Johannes Holtschmidt
15.30	Modulation of neoadjuvant and post-neoadjuvant treatment in HER2+ (pert, TDM1, neratinib, trials)  Johannes Holtschmidt
15.50	Modulation of neoadjuvant and post-neoadjuvant treatment in TNBC (IO, PARPi, capecitabine) Pierfranco Conte
16.10	Indication to and modalities of neoadjuvant Tx in HR+HER2 - BC Valentina Guarneri
16.30	Discussion
17.00	Adjourn
17.15	Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2024 (non CME session)
17.30	Lecture of the Awardee
18.00	Adjourn and cocktail
Friday, October 25 <sup>th</sup>	
	SESSION IV – EARLY BREAST CANCER Chairpersons: Valentina Guarneri, Aleix Prat
9 00	Enhancing efficacy of hormonal therapy in early breast cancer

SESSION III – EARLY BREAST CANCER: NEOADJUVANT

# 9.00 Enhancing efficacy of hormonal therapy in early breast cancer (bisphosphonates, extended, CDK4/6i, SERDs, PARPi...) Stephen Johnston 9.20 Optimizing systemic treatment for small tumors depending on local treatments Hope Rugo 9.40 The challenge of lobular breast cancer Maria Vittoria Dieci

Discussion

10.00

#### 10.30 Coffee break

# 11.00 Clinical Multidisciplinary Shooting Session 1 Early Breast Cancer

Panelists: Bettina Borisch, Hesham Ahmed Gaballah Elghazaly, Oreste Gentilini, Johannes Holtschmidt, Jacek Jassem, Eleftherios Mamounas, Fedro A. Peccatori, Philip Poortmans, Aleix Prat

#### 12.30 Lunch

# SESSION V – METASTATIC BREAST CANCER: CONSOLIDATED AND NEW ALGORITHMS

Chairpersons: Pierfranco Conte, Sandra Swain

#### 13.30 HR+ disease

**Current algorithm:** Claudio Vernieri

Adapting the algorithm in a contemporary scenario: Carmen Criscitiello

#### 14.00 HER2+ disease

Current algorithm: Federica Miglietta

Treatment sequences in new emerging populations: Sandra Swain

#### 14.30 Triple negative disease

Current algorithm: Gaia Griguolo

Treatment sequences in new emerging populations: Hope Rugo

#### 15.00 Discussion

## 15.20 Clinical Multidisciplinary Shooting Session 2 Advanced Breast Cancer

Panelists: Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly, Oreste Gentilini, Stephen Johnston, Philip Poortmans, Hope Rugo, Sandra Swain

#### 16.40 Take home messages and adjourn

Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans

## Honorary President

#### Gabriel N. Hortobagyi

Department of Breast Medical Oncology The University of Texas - MD Anderson Cancer Center Houston (USA)

## **Directors**

#### Pierfranco Conte

Coordinator Molecular Tumor Board, Rete Oncologica Veneta, Padova (I) Scientific Director S. Camillo Hospital, IRCCS, Venezia (I)

#### Valentina Guarneri

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

#### Philip Poortmans

Former president of ESTRO and of ECCO Department of Radiation Oncology Iridium Netwerk University of Antwerp Wilrijk-Antwerp (B)

#### Aleix Prat

Medical Oncology Department Hospital Clinic Barcelona (ES)

## Scientific Committee

#### Bettina Borisch

Institute of Global Health University of Geneva (CH)

#### Maria Vittoria Dieci

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

#### Hesham Ahmed Gaballah Elghazaly

Department of Clinical Oncology and nuclear medicine University of Ainshams Cairo (EG)

#### Jacek Jassem

Department of Oncology and Radiotherapy Medical University of Gdansk (PL)

#### Stephen Johnston

NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)

#### Sibylle Loibl

German Breast Group University of Frankfurt (D)

#### **Eleftherios Mamounas**

Orlando Health Cancer Institute Orlando (F)

#### Fedro Alessandro Peccatori

Department of Medical Oncology European Institute of Oncology (IEO) Milano (I)

#### Sandra Swain M.

Professor of Medicine, Associate Dean Research Development Georgetown University Medical Center Washington (USA)

## Speakers & Chairpersons

#### Carmen Criscitiello

Development Division of New Drugs for Innovative Therapies Istituto Europeo di Oncologia (IEO) Milano (I)

#### Oreste Davide Gentilini

Breast Unit IRCCS S. Raffaele Hospital Milano (I)

#### Gaia Griguolo

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

#### Johannes Holtschmidt

German Breast Group University of Frankfurt (D)

#### Marleen Kok

Breast cancer immunotherapy Netherlands Cancer Institute Amsterdam (NL)

#### Federica Miglietta

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

#### Mafalda Oliveira

Medical Department of the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO) Barcellona (E)

#### Hope Rugo

Breast Oncology Clinical Trials Program UCSF Carol Franc Buck Breast Care Center San Francisco (USA)

#### Angela Toss

Oncology Unit AOU Modena (I)

#### Claudio Vernieri

Institute of Molecular Oncology Oncology and Hemato-Oncology Department IRCCS Istituto Nazionale dei Tumori Milano (I)

#### Alberto Zambelli

Oncology Unit IRCCS Humanitas Rozzano – Milano (I)

## Award & Fellowships

#### **UNIVERSITY OF PADOVA AWARD FOR ADVANCES IN BREAST CANCER 2024**

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The Scientific Committee will select the final winner which will be invited to present his/her study during the annual Conference.

#### **FELLOWSHIPS**

Some fellowship (for under 40) will be awarded including registration, 1 hotel night and reimbursement of travel expenses (max of travel reimbursement 200,00).

#### **UNDER 40**

Accademia will provide a limited amount of free registrations for Physicians, Biologists, Pharmacists and Nurses "Under 40".





Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-419161): 7,7 CME points.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

To obtain CME credits, participants must meet the following requirements:

- 1. Their declared profession/specialization must correspond to those accredited for CME;
- 2. They must attend at least 90% of the course;
- 3. They must complete the online meeting evaluation form;
- 4. They must pass the learning assessment test with at least 75% correct answers. Only one attempt is allowed.

The learning assessment test and meeting evaluation form must be submitted within three days of the event.

## Registration

Online registration at <a href="https://fad.accmed.org/course/info.php?id=1576">https://fad.accmed.org/course/info.php?id=1576</a> before October 19th; the application will be completed only after the payment of the registration fee:

- € 120,00
- € 80,00 for graduate students
- € 80,00 for AIOM members

#### **CANCELLATION AND REFOUNDS**

• In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.

# Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

## Meeting Venue

Auditorium Centro Culturale San Gaetano Altinate Via Altinate, 71 Padova

### How to reach the venue:

The Center is located in the ZTL area.

We recommend the parking in Piazza Insurrezione in the historic center of Padova (the area is accessible and there are no electronic gates).

# Supported by unrestricted educational grants from

SILVER SPONSOR



**BRONZE SPONSOR** 













**CONTRIBUTORS** 









# With the patronage of

#### **INSTITUTIONS**













#### **SCIENTIFIC SOCIETIES**















